Mebanazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mebanazine
Accession Number
DB09248
Type
Small Molecule
Groups
Withdrawn
Description

Mebanazine (trade name Actomol) is a monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was previously used as an antidepressant in the 1960s, but has since been discontinued.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Actomol
Categories
UNII
Z5R55CJ4CG
CAS number
65-64-5
Weight
Average: 136.198
Monoisotopic: 136.100048394
Chemical Formula
C8H12N2
InChI Key
HHRZAEJMHSGZNP-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3
IUPAC Name
(1-phenylethyl)hydrazine
SMILES
CC(NN)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Mebanazine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Mebanazine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Mebanazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Mebanazine.Experimental, Illicit
4-MethoxyamphetamineMebanazine may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Mebanazine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineMebanazine may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Abediterol.Investigational
AcarboseMebanazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololMebanazine may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Mebanazine.Experimental
AlbiglutideMebanazine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mebanazine.Approved, Illicit
AliskirenMebanazine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Mebanazine.Approved, Investigational
AlogliptinMebanazine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mebanazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Mebanazine.Illicit
AlprenololMebanazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Mebanazine.Approved
AmbrisentanMebanazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineMebanazine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineMebanazine may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideMebanazine may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineMebanazine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineMebanazine may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mebanazine.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Mebanazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Arformoterol.Approved, Investigational
AtenololMebanazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineMebanazine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineMebanazine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bambuterol.Approved, Investigational
BenazeprilMebanazine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMebanazine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Mebanazine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mebanazine.Approved, Illicit
BepridilMebanazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Mebanazine.Approved, Investigational
BetaxololMebanazine may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineMebanazine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bezafibrate.Approved, Investigational
BietaserpineMebanazine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostMebanazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololMebanazine may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bitolterol.Withdrawn
BosentanMebanazine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Mebanazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumMebanazine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Mebanazine.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Brimonidine.Approved
BrofaromineMebanazine may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Mebanazine.Approved, Investigational
BupranololMebanazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Mebanazine is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mebanazine.Approved, Illicit, Vet Approved
ButriptylineMebanazine may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Mebanazine.Approved
CadralazineMebanazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineMebanazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinMebanazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanMebanazine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilMebanazine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilMebanazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilMebanazine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mebanazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mebanazine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Mebanazine.Approved, Investigational
CaroxazoneMebanazine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololMebanazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolMebanazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololMebanazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideMebanazine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Mebanazine.Illicit, Withdrawn
ChlorpropamideMebanazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneMebanazine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineMebanazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMebanazine may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Mebanazine.Approved, Investigational
CirazolineMebanazine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Mebanazine.Approved
ClemastineMebanazine may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineMebanazine may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineMebanazine may increase the hypertensive activities of Clonidine.Approved
CloranololMebanazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mebanazine.Approved, Illicit
CryptenamineMebanazine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Mebanazine.Approved
CyclopenthiazideMebanazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideMebanazine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineMebanazine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinMebanazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mebanazine.Investigational
DebrisoquinMebanazine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilMebanazine may increase the hypotensive activities of Delapril.Investigational
DeserpidineMebanazine may increase the hypotensive activities of Deserpidine.Approved
DesipramineMebanazine may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Mebanazine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateMebanazine may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Mebanazine.Approved, Illicit
DextromethorphanMebanazine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mebanazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mebanazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mebanazine.Approved, Investigational
DiazoxideMebanazine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinMebanazine may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineMebanazine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionMebanazine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineMebanazine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mebanazine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Mebanazine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mebanazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mebanazine.Experimental, Illicit
DiltiazemMebanazine may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineMebanazine may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mebanazine.Approved, Illicit
DipivefrinMebanazine may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideMebanazine may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Mebanazine is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Mebanazine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideMebanazine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinMebanazine may increase the serotonergic activities of Dosulepin.Approved
DoxapramMebanazine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinMebanazine may increase the hypotensive activities of Doxazosin.Approved
DoxepinMebanazine may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Doxofylline.Approved, Investigational
DoxylamineMebanazine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mebanazine.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Mebanazine.Experimental, Illicit
DroxidopaMebanazine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideMebanazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Mebanazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Mebanazine.Experimental, Illicit
EfonidipineMebanazine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Mebanazine.Approved, Investigational
EmpagliflozinMebanazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMebanazine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMebanazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineMebanazine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Mebanazine.Approved, Investigational
EpanololMebanazine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Mebanazine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineMebanazine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolMebanazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMebanazine may increase the hypotensive activities of Eprosartan.Approved
ErgonovineMebanazine may increase the hypertensive activities of Ergonovine.Approved
ErgotamineMebanazine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Mebanazine.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Mebanazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mebanazine.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Mebanazine.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mebanazine.Illicit, Vet Approved
ExenatideMebanazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineMebanazine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineMebanazine may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamMebanazine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mebanazine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidMebanazine may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Mebanazine.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mebanazine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Mebanazine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Formoterol.Approved, Investigational
FosinoprilMebanazine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Mebanazine.Approved, Investigational
FurazolidoneMebanazine may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Mebanazine.Experimental
GliclazideMebanazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMebanazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMebanazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideMebanazine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzMebanazine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelMebanazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineMebanazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMebanazine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineMebanazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorMebanazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMebanazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMebanazine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineMebanazine may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mebanazine.Approved, Illicit, Investigational
HexamethoniumMebanazine may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the hypertensive activities of Mebanazine.Experimental
HydralazineMebanazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMebanazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mebanazine.Approved, Illicit
HydroflumethiazideMebanazine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mebanazine.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Mebanazine.Approved
ImidaprilMebanazine may increase the hypotensive activities of Imidapril.Investigational
ImipramineMebanazine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Mebanazine.Investigational, Withdrawn
IndapamideMebanazine may increase the hypotensive activities of Indapamide.Approved
IndenololMebanazine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMebanazine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartMebanazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMebanazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMebanazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMebanazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMebanazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMebanazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Mebanazine.Approved
IprindoleMebanazine may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Mebanazine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Mebanazine.Withdrawn
IrbesartanMebanazine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Mebanazine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Mebanazine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Isoprenaline.Approved, Investigational
IsradipineMebanazine may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinMebanazine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mebanazine.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mebanazine.Approved, Nutraceutical, Withdrawn
LabetalolMebanazine may increase the hypotensive activities of Labetalol.Approved
LacidipineMebanazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostMebanazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineMebanazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Mebanazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mebanazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Mebanazine.Approved, Investigational
LevonordefrinMebanazine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mebanazine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Mebanazine is combined with Linezolid.Approved, Investigational
LinsidomineMebanazine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideMebanazine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Mebanazine.Approved, Investigational
LisinoprilMebanazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Mebanazine.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Mebanazine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mebanazine.Illicit
LofepramineMebanazine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Mebanazine.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Mebanazine.Approved
LosartanMebanazine may increase the hypotensive activities of Losartan.Approved
MacitentanMebanazine may increase the hypotensive activities of Macitentan.Approved
ManidipineMebanazine may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Maprotiline.Approved, Investigational
MecamylamineMebanazine may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminMebanazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenMebanazine may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Mebanazine.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Mebanazine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Mebanazine.Experimental
MequitazineMebanazine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolMebanazine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminMebanazine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Mebanazine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mebanazine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Mebanazine.Approved, Illicit
MethoserpidineMebanazine may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineMebanazine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Mebanazine.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Mebanazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Mebanazine.Experimental
Methylene blueMebanazine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateMebanazine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Mebanazine.Approved
MetipranololMebanazine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMebanazine may increase the hypotensive activities of Metolazone.Approved
MetoprololMebanazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineMebanazine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mebanazine is combined with Mianserin.Approved, Investigational
MibefradilMebanazine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineMebanazine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Mebanazine.Experimental, Illicit, Investigational
MifepristoneMebanazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMebanazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Mebanazine.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Mebanazine.Approved
MinoxidilMebanazine may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Mebanazine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Mebanazine is combined with Moclobemide.Approved, Investigational
MoexiprilMebanazine may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Mebanazine.Approved, Investigational
MoxonidineMebanazine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineMebanazine may increase the hypotensive activities of Muzolimine.Experimental
NadololMebanazine may increase the hypotensive activities of Nadolol.Approved
NaftopidilMebanazine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mebanazine.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Mebanazine.Investigational
NaphazolineMebanazine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Mebanazine.Approved, Investigational
NateglinideMebanazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololMebanazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mebanazine.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Mebanazine.Withdrawn
NicardipineMebanazine may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilMebanazine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineMebanazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMebanazine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineMebanazine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineMebanazine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineMebanazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideMebanazine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineMebanazine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mebanazine.Approved, Illicit
NortriptylineMebanazine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinMebanazine may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineMebanazine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanMebanazine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Olodaterol.Approved
OmapatrilatMebanazine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolMebanazine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mebanazine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Orciprenaline.Approved
OxprenololMebanazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Mebanazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineMebanazine may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mebanazine.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Mebanazine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mebanazine.Approved, Investigational
PenbutololMebanazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineMebanazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mebanazine.Approved, Vet Approved
PentoliniumMebanazine may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Mebanazine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilMebanazine may increase the hypotensive activities of Perindopril.Approved
PethidineMebanazine may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Mebanazine is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Mebanazine.Experimental
PhendimetrazineMebanazine may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Mebanazine.Approved
PheniprazineMebanazine may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Mebanazine.Experimental
PhenoxybenzamineMebanazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineMebanazine may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mebanazine.Approved, Illicit
PhentolamineMebanazine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineMebanazine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Mebanazine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Mebanazine.Investigational
PinacidilMebanazine may increase the hypotensive activities of Pinacidil.Approved
PindololMebanazine may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneMebanazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Mebanazine.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Mebanazine.Approved
PivhydrazineMebanazine may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenMebanazine may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorMebanazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideMebanazine may increase the hypotensive activities of Polythiazide.Approved
PramlintideMebanazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinMebanazine may increase the hypotensive activities of Prazosin.Approved
ProcaineMebanazine may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineMebanazine may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Procaterol.Approved, Investigational
PropranololMebanazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Protokylol.Approved, Vet Approved
ProtriptylineMebanazine may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Mebanazine.Approved
QuinaprilMebanazine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineMebanazine may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineMebanazine may increase the hypertensive activities of Racepinephrine.Approved
RamiprilMebanazine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Mebanazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mebanazine.Approved
RemikirenMebanazine may increase the hypotensive activities of Remikiren.Approved
RepaglinideMebanazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMebanazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Reserpine.Approved, Investigational
RilmenidineMebanazine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatMebanazine may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Mebanazine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Mebanazine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Mebanazine.Approved, Investigational
RosiglitazoneMebanazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Mebanazine.Approved
SafrazineMebanazine may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salmeterol.Approved
SaprisartanMebanazine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinMebanazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Mebanazine.Approved, Investigational, Vet Approved
SelexipagMebanazine may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Mebanazine.Approved
SitagliptinMebanazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanMebanazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilMebanazine may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mebanazine.Approved, Investigational
SulfadiazineMebanazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleMebanazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleMebanazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Mebanazine.Approved, Investigational
SunitinibMebanazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololMebanazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mebanazine.Approved
TelmisartanMebanazine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilMebanazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Terbutaline.Approved
TerlipressinMebanazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Mebanazine.Investigational
TetrahydropalmatineMebanazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineMebanazine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineMebanazine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Mebanazine.Approved, Investigational
TiboloneMebanazine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMebanazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Mebanazine.Experimental
TimololMebanazine may increase the hypotensive activities of Timolol.Approved
TolazamideMebanazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineMebanazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideMebanazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Mebanazine.Approved, Withdrawn
TolonidineMebanazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Mebanazine.Approved
TorasemideMebanazine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Mebanazine.Approved, Investigational
TrandolaprilMebanazine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Mebanazine.Approved, Investigational
TravoprostMebanazine may increase the hypotensive activities of Travoprost.Approved
TrazodoneMebanazine may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilMebanazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideMebanazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinMebanazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanMebanazine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineMebanazine may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneMebanazine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilMebanazine may increase the hypotensive activities of Urapidil.Investigational
ValsartanMebanazine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Mebanazine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Mebanazine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Mebanazine.Approved
VincamineMebanazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMebanazine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Mebanazine.Approved, Investigational
XipamideMebanazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMebanazine may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Mebanazine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Mebanazine.Approved
ZofenoprilMebanazine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Mebanazine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Gilmour SJ: Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry. 1965 Sep;111(478):899-902. [PubMed:5889715]
  2. Barker JC, Jan IA, Enoch MD: A controlled trial of mebanazine ('Actomol') in depression. Br J Psychiatry. 1965 Nov;111(480):1095-100. [PubMed:5320546]
  3. Knott F: A preliminary trial of mebanazine in depressive states. J New Drugs. 1965 Nov-Dec;5(6):345-7. [PubMed:5327282]
External Links
PubChem Compound
6179
PubChem Substance
310265151
ChemSpider
5944
ChEBI
134728
ChEMBL
CHEMBL1909283
Wikipedia
Mebanazine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.6 mg/mLALOGPS
logP1.24ALOGPS
logP1.33ChemAxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity53.93 m3·mol-1ChemAxon
Polarizability15.65 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Alkylhydrazine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Hydrazine derivative / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 21:57 / Updated on July 02, 2018 19:13